Novartis buys Ebewe injectables unit - Pharmaceutical Executive


Novartis buys Ebewe injectables unit

Novartis AG has agreed to buy Ebewe Pharma's injectables unit for $1.2 billion in an all-cash transaction.

The deal excludes Ebewe's neurological products business but will enable Novartis to add generic cancer drugs to its offerings.

Ebewe, based in Austria, generated EUR 188 million in sales last year and EUR 53 million in operating profit.


blog comments powered by Disqus

Serialization Summit
San Diego, CA
Feb. 27-28, 2014

Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014

ClinTech 2014
Cambridge, MA
Mar. 11-13 2014

Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Click here